Peter  Fasolo net worth and biography

Peter Fasolo Biography and Net Worth

Peter M. Fasolo is Executive Vice President, Chief Human Resources Officer, responsible for global talent, recruiting, diversity and inclusion, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. He is a member of the Executive Committee, Management Compensation Committee, and Chairman of the Pension and Benefits Committee.

Peter first joined Johnson & Johnson in 2004 as Worldwide Vice President, Human Resources for Cordis Corporation. He was then named Vice President, Global Talent Management, with responsibility for executive assessment and development. He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. (KKR) as Chief Talent Officer for the portfolio companies owned by the firm. He returned to Johnson & Johnson in September 2010 as Vice President, Global Human Resources.

Peter has more than 25 years of global experience in healthcare, having spent 13 years with Bristol-Myers Squibb in executive level, human resource roles in the pharmaceutical, medical devices and consumer segments. He serves on the Boards of the Human Resources Policy Association in Washington, D.C., Tufts University and Save the Children and was named a Fellow of the National Academy of Human Resources in 2017.

Peter earned a Ph.D. in Organizational Behavior from the University of Delaware, a Master of Arts degree in Industrial Psychology from Fairleigh Dickinson University and a Bachelor of Arts degree in Psychology from Providence College.

What is Peter Fasolo's net worth?

The estimated net worth of Peter Fasolo is at least $14.87 million as of July 25th, 2023. Dr. Fasolo owns 102,696 shares of Johnson & Johnson stock worth more than $14,867,300 as of April 18th. This net worth approximation does not reflect any other assets that Dr. Fasolo may own. Additionally, Dr. Fasolo receives a salary of $2,150,000.00 as VP at Johnson & Johnson. Learn More about Peter Fasolo's net worth.

How old is Peter Fasolo?

Dr. Fasolo is currently 61 years old. There are 5 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who is 66 years old. Learn More on Peter Fasolo's age.

What is Peter Fasolo's salary?

As the VP of Johnson & Johnson, Dr. Fasolo earns $2,150,000.00 per year. There are 3 executives that earn more than Dr. Fasolo. The highest earning executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who commands a salary of $8,570,000.00 per year. Learn More on Peter Fasolo's salary.

How do I contact Peter Fasolo?

The corporate mailing address for Dr. Fasolo and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Peter Fasolo's contact information.

Has Peter Fasolo been buying or selling shares of Johnson & Johnson?

Peter Fasolo has not been actively trading shares of Johnson & Johnson in the last ninety days. Most recently, Peter Fasolo sold 20,000 shares of the business's stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a transaction totalling $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company's stock, valued at $17,491,182.72. Learn More on Peter Fasolo's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (Insider), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 5 times. They sold a total of 110,285 shares worth more than $17,306,967.44. The most recent insider tranaction occured on February, 16th when Major Shareholder & Johnson Johnson sold 3,725 shares worth more than $96,142.25. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 2/16/2024.

Peter Fasolo Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2023Sell20,000$170.32$3,406,400.00102,696View SEC Filing Icon  
10/24/2022Sell29,275$171.36$5,016,564.00114,676View SEC Filing Icon  
10/19/2022Sell22,864$164.50$3,761,128.00114,676View SEC Filing Icon  
12/4/2018Sell166,695$146.41$24,405,814.95155,540View SEC Filing Icon  
2/3/2016Sell151,385$104.12$15,762,206.2037,735View SEC Filing Icon  
3/14/2014Sell6,824$93.15$635,655.6015,647View SEC Filing Icon  
See Full Table

Peter Fasolo Buying and Selling Activity at Johnson & Johnson

This chart shows Peter Fasolo's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $144.77
Low: $143.54
High: $145.41

50 Day Range

MA: $156.54
Low: $144.45
High: $162.73

2 Week Range

Now: $144.77
Low: $143.39
High: $175.97

Volume

9,302,952 shs

Average Volume

6,804,006 shs

Market Capitalization

$348.86 billion

P/E Ratio

9.03

Dividend Yield

3.30%

Beta

0.53